Viewing nowValsan 80mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Myungmoon Pharmaceuticals Co., Ltd.

MFDS item code 201110105 · Approved 2011.11.16 · Insurance code 649805500
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medicine is mainly used for the treatment of essential hypertension. It is also effective in patients with heart failure who are intolerant to ACE inhibitors, particularly those classified as NYHA class II to IV. It is utilized to reduce the risk of mortality in patients with left ventricular dysfunction or contractile dysfunction following myocardial infarction. Thus, it helps in managing hypertension, improving heart failure symptoms, and enhancing survival rates after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The antihypertensive effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily, or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience of use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus if taken during pregnancy, therefore, it should be discontinued immediately if pregnancy is confirmed. Do not take if you have an allergy to this drug or its ingredients, if you are pregnant or may become pregnant, if you are nursing, if you have severe liver impairment, hereditary angioedema, or severe renal impairment. Caution is needed for elderly patients, patients with high potassium levels, mild to moderate liver impairment, heart valve disease, and patients with cardiovascular disease when using this medication. As this drug has a strong blood pressure-lowering effect, dizziness or fainting may occur due to sharp drops in blood pressure when starting treatment, particularly for patients with low fluids or sodium levels who should increase their dosage slowly. Patients undergoing hemodialysis or those on strict salt restrictions should be closely monitored when starting this drug. This drug may increase potassium levels, so potassium-sparing diuretics or potassium supplements should be monitored closely. Additionally, taking this drug with certain non-steroidal anti-inflammatory drugs (NSAIDs) may reduce its blood pressure-lowering effect or worsen renal function, so caution is warranted. This medication is not recommended for nursing women; if unavoidable, breastfeeding should be discontinued. Possible adverse effects include headache, dizziness, fatigue, cough, and gastrointestinal disturbances, while serious effects may involve angioedema, renal dysfunction, and hypotension, so consulting with healthcare professionals immediately upon symptoms is necessary. In cases of overdose, hypotension, decreased consciousness, and shock may be expected, requiring immediate emergency care; hemodialysis is ineffective. Safety and efficacy in pediatric patients and adolescents are not established, so caution is required when used in this population. Lastly, this medication should be stored out of reach of children, and transferring to another container is not good for quality maintenance, so care should be taken.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Light pink, double convex, round film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Myungmoon Pharmaceuticals Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.